Can CBD Live up to the Hype? Rabobank Liquid Assets Podcast
![Pic:getty/alexandrkravtsov](/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/publications/food-beverage-nutrition/beveragedaily.com/article/2019/05/22/can-cbd-live-up-to-the-hype-rabobank-liquid-assets-podcast/9483467-3-eng-GB/Can-CBD-Live-up-to-the-Hype-Rabobank-Liquid-Assets-Podcast.jpg)
CBD is the most exciting and perhaps controversial new ingredient in decades: and this guest podcast from Rabobank looks at whether it's going to be a big deal - or a big disappointment.
Despite a government crackdown on illegal sales, consumers are clamoring for CBD-infused products. This podcast from Rabobank explores what is driving demand for CBD, and lays out the best - and worst - case scenarios for the development of the CBD market.
This episode - which you can listen to below - features Global Strategist Stephen Rannekleiv, Senior Analyst Jim Watson, and Analyst Bourcard Nesin.
Major topics Covered in the Episode:
- What is the legal situation for CBD in food and beverage products, and if CBD is illegal, why is the FDA allowing companies to sell it?
- Why do consumers want CBD? From treating medical conditions to a perceived health halo.
- The headwinds that could sabotage CBD: the taste of cannabis products; whether purported benefits can be proven; and its regulatory status.
- What opportunities are driving companies to take the risk of selling illegal products?